PMI and BAT Resolve Intellectual Property Dispute

BATPMI by 2FIRSTS.ai
Feb.03.2024
PMI and BAT Resolve Intellectual Property Dispute
Philip Morris International (PMI) and British American Tobacco (BAT) have resolved their intellectual property dispute over heated tobacco and e-cigarette products.

On February 2nd, in the Eastern Time Zone of the United States, both Philip Morris International (PMI) and British American Tobacco (BAT) announced on their respective official websites that they have resolved their intellectual property dispute regarding heated tobacco and e-cigarette products.

 

PMI and BAT Resolve Intellectual Property Dispute
PMI Press Release | Image Source: PMI Official Website

 

British American Tobacco (BAT) and Philip Morris International (PMI) have announced a settlement agreement that includes non-monetary terms between the two companies. This agreement resolves all ongoing global patent infringement lawsuits, including any related injunctions and exclusions, and prevents future claims against current heated tobacco and vaping products. The settlement also allows both parties to continue innovating and launching improved versions of their products. Both companies are committed to ongoing innovation in the reduced-risk product space, furthering efforts to reduce the harm caused by tobacco.

 

PMI and BAT Resolve Intellectual Property Dispute
BAT News Just In | Image Source: BAT Official Website.

 

These two international tobacco companies have been embroiled in a multifaceted patent war. BAT's e-cigarette brand VUSE and heat-not-burn tobacco device brand GLO suffered a defeat in one case, being ordered to pay millions of dollars; while PMI was prohibited from introducing its flagship heat-not-burn tobacco device IQOS into the United States due to another lawsuit.

 

PMI CEO, Jacek Olczak, expressed satisfaction with the resolution, stating, "We are pleased that both parties are content with the outcome. Adult smokers worldwide consistently display a desire for a range of smoke-free products, and we believe that continued innovation in reduced-risk alternatives can expedite the reduction of smoking-related harms, benefiting consumers and public health as a whole. Meanwhile, we will remain committed to phasing out the sale of traditional cigarettes as part of PMI's journey.

 

BAT CEO Tadeu Marroco has expressed his satisfaction with the recent agreement, stating, "This agreement is a significant step forward for BAT and all our stakeholders. With the successful development of our billion-pound brands VUSE and GLO, the potential for reducing tobacco harm is evident. I am pleased that this settlement will allow BAT to focus on developing innovative solutions to provide adult consumers with reduced-risk products and contribute to our 'A Better Tomorrow' mission. By doing so, we will help build a smoke-free world for consumers, investors, and society as a whole."

 

2FIRSTS has invited Chinese e-cigarette legal expert Counsellor Tang Shunliang to provide a professional analysis of the background and potential impact of the patent settlement between PMI and BAT. An article providing this analysis will be published later. Stay tuned.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

FDA and NIH Release New Wave 8 Restricted-Use PATH Study Data Files
FDA and NIH Release New Wave 8 Restricted-Use PATH Study Data Files
FDA’s Center for Tobacco Products and NIH’s National Institute on Drug Abuse announced that new Wave 8 restricted-use data files from the PATH Study are now available. The files contain data collected between January 2024 and December 2024, including questionnaire data, location characteristics data, and state identifier data.
Apr.17 by 2FIRSTS.ai
Acting CTP Director Says FDA Cut Premarket Tobacco Application Backlog by About 70% Over the Past Year
Acting CTP Director Says FDA Cut Premarket Tobacco Application Backlog by About 70% Over the Past Year
FDA Center for Tobacco Products Acting Director Bret Koplow said at the American Tobacco and Nicotine Forum that the agency has reduced its premarket tobacco application backlog by about 70% over the past year and eliminated the acceptance queue. He said FDA has reviewed about 27 million applications, but only a small number have been authorized, mainly because most submissions lacked the scientific data needed to demonstrate public health benefits.
Apr.23 by 2FIRSTS.ai
Fifth Circuit Hears Challenge to FDA’s Standard for Reviewing Flavored Vape Applications
Fifth Circuit Hears Challenge to FDA’s Standard for Reviewing Flavored Vape Applications
A three-judge panel of the U.S. Court of Appeals for the Fifth Circuit heard oral arguments on Tuesday in a case brought by seven small vape-liquid companies challenging the Food and Drug Administration’s denial of marketing authorization for their flavored electronic nicotine products.
Apr.30 by 2FIRSTS.ai
Capital Group Takes 5.61% Stake in KT&G, Joining Major Foreign Shareholders
Capital Group Takes 5.61% Stake in KT&G, Joining Major Foreign Shareholders
KT&G disclosed in a regulatory filing on Friday that Capital Research and Management Company, the investment management arm of Capital Group, had acquired a 5.61% stake through purchases made on April 22 and May 4. The move places Capital Group among KT&G’s prominent foreign shareholders, alongside BlackRock, First Eagle Investment Management and Singapore’s sovereign wealth fund GIC.
May.08 by 2FIRSTS.ai
 FDA Begins Review of 22nd Century’s VLN MRTP Renewal Applications
FDA Begins Review of 22nd Century’s VLN MRTP Renewal Applications
The U.S. Food and Drug Administration (FDA) has initiated scientific review of renewal applications for 22nd Century Group’s VLN reduced-nicotine cigarettes under the Modified Risk Tobacco Product (MRTP) pathway, with current authorizations set to expire in December 2026.
News
May.13
From Brands to Supply Chains: 2Firsts Builds a PMTA Compliance Service System for the U.S. Market
From Brands to Supply Chains: 2Firsts Builds a PMTA Compliance Service System for the U.S. Market
2Firsts supports new tobacco and nicotine companies entering the U.S. market with full-chain PMTA compliance services.
Jun.04